Literature DB >> 21336563

Mechanisms of HIV-1 Nef function and intracellular signaling.

John L Foster1, Sarah J Denial, Brenda R S Temple, J Victor Garcia.   

Abstract

Advances in the last several years have enhanced mechanistic understanding of Nef-induced CD4 and MHCI downregulation and have suggested a new paradigm for analyzing Nef function. In both of these cases, Nef acts by forming ternary complexes with significant contributions to stability imparted by non-canonical interactions. The mutational analyses and binding assays that have led to these conclusions are discussed. The recent progress has been dependent on conservative mutations and multi-protein binding assays. The poorly understood Nef functions of p21 activated protein kinase (PAK2) activation, enhancement of virion infectivity, and inhibition of immunoglobulin class switching are also likely to involve ternary complexes and non-canonical interactions. Hence, investigation of these latter Nef functions should benefit from a similar approach. Six historically used alanine substitutions for determining structure-function relationships of Nef are discussed. These are M20A, E62A/E63A/E64A/E65A (AAAA), P72A/P75A (AXXA), R106A, L164A/L165A, and D174A/D175A. Investigations of less-disruptive mutations in place of AAAA and AXXA have led to different interpretations of mechanism. Two recent examples of this alternate approach, F191I for studying PAK2 activation and D123E for the critical residue D123 are discussed. The implications of the new findings and the resulting new paradigm for Nef structure-function are discussed with respect to creating a map of Nef functions on the protein surface. We report the results of a PPI-Pred analysis for protein-protein interfaces. There are three predicted patches produced by the analysis which describe regions consistent with the currently known mutational analyses of Nef function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21336563      PMCID: PMC3777542          DOI: 10.1007/s11481-011-9262-y

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  127 in total

1.  HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway.

Authors:  Anastassia D Blagoveshchenskaya; Laurel Thomas; Sylvain F Feliciangeli; Chien Hui Hung; Gary Thomas
Journal:  Cell       Date:  2002-12-13       Impact factor: 41.582

2.  Species-specific effects of HIV-1 Nef-mediated MHC-I downmodulation.

Authors:  Rebekah Fleis; Tracey Filzen; Kathleen L Collins
Journal:  Virology       Date:  2002-11-10       Impact factor: 3.616

3.  A hydrophobic binding surface on the human immunodeficiency virus type 1 Nef core is critical for association with p21-activated kinase 2.

Authors:  Kristin Agopian; Bangdong L Wei; J Victor Garcia; Dana Gabuzda
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

4.  Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors.

Authors:  Robin W Freeburn; Karen L Wright; Steven J Burgess; Emmanuelle Astoul; Doreen A Cantrell; Stephen G Ward
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

Review 5.  Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways.

Authors:  Jeremiah F Roeth; Kathleen L Collins
Journal:  Microbiol Mol Biol Rev       Date:  2006-06       Impact factor: 11.056

6.  Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells.

Authors:  Xugang Qiao; Bing He; April Chiu; Daniel M Knowles; Amy Chadburn; Andrea Cerutti
Journal:  Nat Immunol       Date:  2006-01-22       Impact factor: 25.606

7.  Human immunodeficiency virus type-1 infection impairs the formation of the immunological synapse.

Authors:  Maria Isabel Thoulouze; Nathalie Sol-Foulon; Fabien Blanchet; Alice Dautry-Varsat; Olivier Schwartz; Andrés Alcover
Journal:  Immunity       Date:  2006-05       Impact factor: 31.745

8.  The Pro78 residue regulates the capacity of the human immunodeficiency virus type 1 Nef protein to inhibit recycling of major histocompatibility complex class I molecules in an SH3-independent manner.

Authors:  Nicoletta Casartelli; Giorgia Giolo; Francesca Neri; Claudia Haller; Marina Potestà; Paolo Rossi; Oliver T Fackler; Margherita Doria
Journal:  J Gen Virol       Date:  2006-08       Impact factor: 3.891

9.  Differential expression of protein tyrosine kinase genes during microglial activation.

Authors:  J Kyle Krady; Anirban Basu; Steven W Levison; Robert J Milner
Journal:  Glia       Date:  2002-10       Impact factor: 7.452

10.  Proline 78 is crucial for human immunodeficiency virus type 1 Nef to down-regulate class I human leukocyte antigen.

Authors:  Takeshi Yamada; Naotoshi Kaji; Takashi Odawara; Joe Chiba; Aikichi Iwamoto; Yoshihiro Kitamura
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  38 in total

1.  Single-domain antibody-SH3 fusions for efficient neutralization of HIV-1 Nef functions.

Authors:  Jérôme Bouchet; Cécile Hérate; Carolin A Guenzel; Christel Vérollet; Annika Järviluoma; Julie Mazzolini; Salomeh Rafie; Patrick Chames; Daniel Baty; Kalle Saksela; Florence Niedergang; Isabelle Maridonneau-Parini; Serge Benichou
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

2.  A noncanonical mu-1A-binding motif in the N terminus of HIV-1 Nef determines its ability to downregulate major histocompatibility complex class I in T lymphocytes.

Authors:  Sayuki Iijima; Young-Jung Lee; Hirotaka Ode; Stefan T Arold; Nobuyuki Kimura; Masaru Yokoyama; Hironori Sato; Yasuhito Tanaka; Klaus Strebel; Hirofumi Akari
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

3.  Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.

Authors:  Nirmin Alsahafi; Jonathan Richard; Jérémie Prévost; Mathieu Coutu; Nathalie Brassard; Matthew S Parsons; Daniel E Kaufmann; Mark Brockman; Andrés Finzi
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

4.  The Nef-like effect of murine leukemia virus glycosylated gag on HIV-1 infectivity is mediated by its cytoplasmic domain and depends on the AP-2 adaptor complex.

Authors:  Yoshiko Usami; Sergei Popov; Heinrich G Göttlinger
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

5.  Cell signaling pathways and HIV-1 therapeutics.

Authors:  Johnny J He
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-30       Impact factor: 4.147

6.  Nef-mediated inhibition of NFAT following TCR stimulation differs between HIV-1 subtypes.

Authors:  Lisa Naidoo; Zinhle Mzobe; Steven W Jin; Erasha Rajkoomar; Tarylee Reddy; Mark A Brockman; Zabrina L Brumme; Thumbi Ndung'u; Jaclyn K Mann
Journal:  Virology       Date:  2019-02-21       Impact factor: 3.616

Review 7.  14-3-3s are potential biomarkers for HIV-related neurodegeneration.

Authors:  Diana Morales; Efthimios C M Skoulakis; Summer F Acevedo
Journal:  J Neurovirol       Date:  2012-07-19       Impact factor: 2.643

8.  Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence.

Authors:  Andrey Tokarev; John Guatelli
Journal:  Cell Logist       Date:  2011-05

9.  Impaired Nef function is associated with early control of HIV-1 viremia.

Authors:  Xiaomei T Kuang; Xiaoguang Li; Gursev Anmole; Philip Mwimanzi; Aniqa Shahid; Anh Q Le; Louise Chong; Hua Qian; Toshiyuki Miura; Tristan Markle; Bemuluyigza Baraki; Elizabeth Connick; Eric S Daar; Heiko Jessen; Anthony D Kelleher; Susan Little; Martin Markowitz; Florencia Pereyra; Eric S Rosenberg; Bruce D Walker; Takamasa Ueno; Zabrina L Brumme; Mark A Brockman
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

Review 10.  HIV-1 Nef in macrophage-mediated disease pathogenesis.

Authors:  Susanna L Lamers; Gary B Fogel; Elyse J Singer; Marco Salemi; David J Nolan; Leanne C Huysentruyt; Michael S McGrath
Journal:  Int Rev Immunol       Date:  2012-12       Impact factor: 5.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.